0
During a press conference held on 14 November 2020, ‘A new generic medicines market’ strategy was revealed, with which ’the Health and Economic Secretaries will strengthen the companies producing generic medicines, through the linking mechanisms and technological tools, based on the principles of innovation, transparency, competitiveness and legality’ fostering firmly a wider and solid generic medicines market, for the benefit of Mexican nationals.
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
-
Biosimilars
News
- EC approves eight biosimilars, eight more await final authorization
- Canada approves first omalizumab biosimilar Omlyclo
- EMA recommends approval for tocilizumab biosimilar Avtozma and filgrastim biosimilar Zefylti
- Ustekinumab biosimilars Yesintek, Steqeyma, and Otulfi approved by FDA, EMA and Health Canada
Research
- Positive safety and efficacy primary endpoint results for AVT05 (golimumab proposed biosimilar)
- Are interchangeable biosimilars at risk?
- Comparative efficacy studies: where are we now?
- Pertuzumab biosimilar HLX11 meets primary endpoint in phase III comparative clinical study
- MORE EDITORIAL SECTIONS
- Search
Post your comment